louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06054529: Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
Official title: Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Glioblastoma Multiforme
Lead sponsor: AdventHealth Translational Research Institute
Sponsor class: OTHER
First posted: 2023-09-26
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The research being pursued in this study is relevant to all GBM patients including these who are cognitively impaired.

Brief summary: To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness


Eligibility criteria: Inclusion Criteria:

1. Preoperative MRI consistent with a primary intracranial malignant brain tumor.
2. Must be 18 years of age or older.
3. Patient eligible for debulking surgery/resection.

Exclusion Criteria:

1. Inability to obtain pre-operative IV access.
2. Use of Tru Niagen, Basis (or any other nicotinamide riboside (NR)-containing NAD+ booster) or niacin supplements within one month prior to Study Visit 1.
3. Participation in studies involving investigational drug(s) within 30 days prior to Study Visit 1
4. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Study Visit 1 (participants may not donate blood any time during the study, through the final study day)
5. Presence of any condition that, in the opinion of Dr. Field, compromises participant safety or data integrity or the participant's ability to complete study days.
6. Pregnancy, lactation or \< 9 months postpartum from the Study Visit 1 date.

Primary outcomes:
measure: Subtyping of GBM tumors as Classical, Proneural or MES (based on RNA-seq)
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Orlando
country: United States
facility: AdventHealth Translational Research Institute
state: Florida
Study officials:
affiliation: AdventHealth Translational Research Institute
name: Adeline Divoux, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03506529: Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Official title: Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anal Cancer
Keywords: TEP
hypermetabolism
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
First posted: 2018-04-24
Enrollment: 644
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient coming for a PET

Brief summary: Questionnaire to be completed by patients coming for PET to identify the predictive factors of physiological hypermetabolism of the anal canal


Eligibility criteria: Inclusion Criteria:

* Patient 18 years old
* Patient referred for 18F-FDG PET

Exclusion Criteria:

* History of surgery or anal and / or perineal and / or pelvic radiotherapy, whatever the indication
* Patient deprived of liberty, under tutorship or curatorship
* Any associated socio-educational, medical or psychological condition that could compromise the patient's ability to participate in the study (eg illiteracy, mental retardation, etc.)
* Pregnant woman (classic contraindication of a PET scan)
* Opposition of the patient to participate in the study

Primary outcomes:
measure: Description of predictive factors for physiological hypermetabolism of the anal canal in 18F-FDG PET / CT
timeFrame: Only at the day of inclusion, during an appointment for a TEP exam
measure: PET analysis of hypermetabolism of the anal canal
timeFrame: Only at the day of inclusion, during an appointment for a TEP exam
measure: CT scan with measurement
timeFrame: Only at the day of inclusion, during an appointment for a TEP exam
measure: CT scan with measurement
timeFrame: Only at the day of inclusion, during an appointment for a TEP exam
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: CHU
city: Caen
country: France
facility: Centre François Baclesse
Study officials:
References:
citation: Aide N, Tainturier LE, Nganoa C, Houdu B, Kammerer J, Galais MP, Ciappuccini R, Lasnon C. HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake. EJNMMI Res. 2020 Mar 20;10(1):28. doi: 10.1186/s13550-020-0615-5.
Clinical trial NCT05058729: MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
Official title: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) - COVID-19 Questionnaire Linkage Sub-Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis (MS)
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2021-09-28
Enrollment: 1507
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with MS or CIS who are enrolled in MS PATHS under Study 888MS001 and have completed at least one COVID-19 questionnaire administered by a participating healthcare institution will be included in this study.

Brief summary: The primary objective of this sub-study is to supplement the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) dataset with coronavirus disease 2019 (COVID-19)-related health information obtained from periodic participant questionnaires administered by participating MS PATHS institutions.


Eligibility criteria: Key Inclusion Criteria:

1. Be enrolled in MS PATHS under Study 888MS001.
2. Completed one or more COVID-19 questionnaire at a participating MS PATHS institution.
3. Permission for data linkage either obtained when completing a local COVID-19 questionnaire or granted by waiver of informed consent from the local institutional review board (IRB) or ethics committee (EC).

Key Exclusion Criteria:

1. Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the participant unsuitable for participation in the sub-study. A participant only needs to complete the assessments deemed necessary by the Investigator.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: Number of Completed COVID-19 Questionnaires Able to be Linked to a MS PATHS Participant Identifier (ID)
timeFrame: Up to 17 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Research Site
state: Maryland
city: Saint Louis
country: United States
facility: Research Site
state: Missouri
city: Las Vegas
country: United States
facility: Research Site
state: Nevada
city: New York
country: United States
facility: Research Site
state: New York
city: Cleveland
country: United States
facility: Research Site
state: Ohio
city: Columbus
country: United States
facility: Research Site
state: Ohio
Study officials:
affiliation: Biogen
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06323629: Effects of Recursive Self-feedback on Speech Production in Aphasia
Official title: Recursive Self-feedback Procedures for Improving Spontaneous Speech Production in Patients With Chronic Aphasia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Aphasia
Stroke
Lead sponsor: University of South Florida
Sponsor class: OTHER
Collaborators: name: Center for Smart Use of Technologies to Assess Real-world Outcomes
First posted: 2024-03-21
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to test the effects of recursive self-feedback procedures on spontaneous speech production in stroke survivors with impaired speech production (aphasia). The main question it aims to answer is:

• To what extent can stroke survivors with aphasia use their self-feedback alone to improve their spontaneous speech production?

Participants will be engaged in the following activities:

* They will perform language and cognitive tasks.
* Afterwards, they will receive treatments using tablets and headphones at no cost to them.
* The experimental treatments (recursive self-feedback procedures) entails responding to prompts, listening to playbacks of their speech response and attempt to minimize/correct the errors in the next attempt. This process will be repeated multiple times per prompt.
* The experimental treatments are two: an adaptive version that adapts the complexity of the treatment prompt and a non-adaptive version that does not adapt task complexity.
* Researchers will compare the experimental treatments to see if both have similar effects on improving spontaneous speech production.


Eligibility criteria: Inclusion Criteria:

* 6 months post left hemisphere stroke
* Aphasia due to left hemisphere stroke
* Dominant English speaker

Exclusion Criteria:

* Speech-language deficits due to neurological insults such as Parkinson's disease, neurodegenerative conditions etc.
* Uncorrected sensory impairments.
* Language comprehension impairment.
* Severe cognitive impairment.

Primary outcomes:
measure: Speaking rate
timeFrame: Within 1 week before treatment and within 1 week after treatment.
measure: Speech initiation latency in milliseconds
timeFrame: Within 1 week before treatment and within 1 week after treatment.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of South Florida
name: Gerald C. Imaezue, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05542329: Efficiency of a Telemedicine-based Follow-up on for the Medical Management of Patients Leaving the Intensive Care Unit
Official title: Efficiency of a Telemedicine-based Follow-up on for the Medical Management of Patients Leaving the Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Care After Going to Intensive Care
Keywords: Tele-medicine
Intensive Care Unit
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-09-15
Enrollment: 448
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Patients surviving to a stay in intensive care unit (ICU) are likely to require specific care and follow-up after their ICU stay, in order to manage the serious illness at the origin of the ICU stay and any sequelae, but also to adapt the treatments and prevent new complications. At present, there is no specific care chain after ICU.

In order to meet this need, we propose the implementation of a care chain integrating telemedicine at home. We compare the current system (lack of specific follow-up) to follow-up by telemedicine at home.


Eligibility criteria: Inclusion criteria:

* Adult patient ≥ 18 years old
* Patient admitted to ICU
* Stay in intensive care \> 48h
* Patient having benefited from at least one organ support during the ICU stay: invasive or non-invasive ventilation (including nasal high-flow oxygen therapy), inotropic or vasopressor support, renal replacement therapy)
* Understanding of the French language
* Patient or entourage able to carry out the measures proposed by telemedicine
* Subject affiliated to a social health insurance scheme
* Subject having signed a consent form

Exclusion criteria:

* Subject under guardianship or curatorship
* Pregnancy / lactation
* Voluntary drug poisoning

Primary outcomes:
measure: Evaluate the medico-economic of telemedicine monitoring
timeFrame: 12 month
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Service de Réanimation Médicale - CH Dijon
city: Mulhouse
country: France
facility: Service de Réanimation Médicale - CH Mulhouse
city: Nancy
country: France
facility: Service de Réanimation Médicale - CHRU Nancy - France
city: Strasbourg
country: France
facility: Service de Médecine Intensive - Réanimation / CHU Strasbourg - France
Study officials:
References:
Clinical trial NCT00881829: Hypoxia Blood Validation in Multiple Pulse Oximeters
Official title: Accuracy Validation in Multiple SpO2 Systems
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypoxia
Keywords: Pulse Oximetry
Temperature
Respiratory Rate
Respiratory Gases
This study determine the measurement accuracy of the physiological parameters
Lead sponsor: Clinimark, LLC
Sponsor class: OTHER
First posted: 2009-04-15
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of the Denver metropolitan area.

Brief summary: The purpose of this study is to evaluate the SpO2 accuracy and performance of multiple pulse oximeters during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry for SpO2 validation.

This study is observational in nature which quantifies device performance and accuracy in comparison to a Reference Standard.

Detailed description: The purpose of this study is to evaluate the SpO2 accuracy and performance of pulse oximeters during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry for SpO2 validation. The end goal is to show the SpO2 accuracy performance of the pulse oximeters. It is expected that the Accuracy Root Mean Square (Arms) performance of pulse oximeters will meet a specification of 3 or better in non-motion conditions for the range of 70-100% SaO2 thereby demonstrating an acceptable SpO2 accuracy performance specification

Eligibility criteria: Inclusion Criteria:

* healthy individuals between the age of 18-50 years.

Exclusion Criteria:

* Clotting disorders, diabetes, currently taking psychotropic medications.

Primary outcomes:
measure: Completion of study by all subjects
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Louisville
country: United States
facility: Clinimark Laboratories
state: Colorado
Study officials:
affiliation: Avista Adventist Hospital
name: David Ransom, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01838629: the Effect of Universal Salt Iodization on Thyroid Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thyroid Nodule
Lead sponsor: Hangzhou Center of Disease Control and Prevention
Sponsor class: OTHER_GOV
First posted: 2013-04-24
Enrollment: 12438
Sex: ALL
Minimum age (years): 6
Maximum age (years): 86
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This study was conducted in Hangzhou, Zhejiang Province, China, which locates at east of China. This city covers eight districts and five counties. There are 8.7 millions residents in Hangzhou city; 73.25% of them living in urban areas, 26.75% in rural areas. This study was designed to be representative of the civilian from Hangzhou and collected information on demographic characteristics, health status, iodine intake and thyroid disease.

Brief summary: 1. acquire the environmental iodine status of Hangzhou
2. acquire the iodine status of population in Hangzhou
3. acquire the prevalence of thyroid diseases in Hangzhou
4. explore the association between iodized salt and thyroid disease


Eligibility criteria: Inclusion Criteria:

1. age ≥ 6 years old;
2. living for above 5 years at present residence.

Exclusion Criteria:

1. resident with coronary angiography (CAG) or endoscopic retrograde cholangiopancreatography (ERCP) in 6 months;
2. resident taking amiodarone drug;
3. resident with abnormal kidney function or serious illness

Primary outcomes:
measure: thyroid nodule
timeFrame: 8:00am (day 1)
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Hangzhou Center of Disease Control and Prevention
state: Zhejiang
Study officials:
affiliation: Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
name: Weimin Xu
role: PRINCIPAL_INVESTIGATOR
References:
citation: Xu W, Chen Z, Li N, Liu H, Huo L, Huang Y, Jin X, Deng J, Zhu S, Zhang S, Yu Y. Relationship of anthropometric measurements to thyroid nodules in a Chinese population. BMJ Open. 2015 Dec 21;5(12):e008452. doi: 10.1136/bmjopen-2015-008452.
citation: Chen Z, Xu W, Huang Y, Jin X, Deng J, Zhu S, Liu H, Zhang S, Yu Y. Associations of noniodized salt and thyroid nodule among the Chinese population: a large cross-sectional study. Am J Clin Nutr. 2013 Sep;98(3):684-92. doi: 10.3945/ajcn.112.054353. Epub 2013 Jul 10.
Clinical trial NCT05983029: Determination of Utility of Intergluteal Cleft as Landmark for Neuraxial Midline in Obstetrics
Official title: Determination of the Utility of the Intergluteal Cleft as a Landmark for nEuraxial Midline identiFication in obsteTric Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obstetric Anesthesia Problems
Lead sponsor: Guy's and St Thomas' NHS Foundation Trust
Sponsor class: OTHER
First posted: 2023-08-09
Enrollment: 99
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant patients

Brief summary: Our aim is to investigate whether a novel landmark, the groove between the buttocks or the intergluteal cleft, can facilitate the identification of the neuraxial midline in obstetric patients when compared to ultrasound as the reference standard for the determination of this midline

Detailed description: Determine if the intergluteal cleft, when compared to ultrasound as the reference standard, can be used to identify the neuraxial midline in obstetric patients

Difference in horizontal distance between the vertical lines of the intergluteal cleft and the neuraxial midline, the latter measured with ultrasound

Eligibility criteria: Inclusion criteria

* Female
* 18 years of age or older
* Gestation of 37 weeks or above

Exclusion criteria

* Acute or chronic confusional state
* Allergy to ultrasound gel
* Positive for COVID-19 and/or presence of symptoms consistent with SARS-Cov-2, such as anosmia, cough or fever
* History of previous surgery to the spine
* Scoliosis
* Unable to speak and/or understand English

Primary outcomes:
measure: Horizontal distance between intergluteal cleft and neuraxial midline
timeFrame: 12 months
Secondary outcomes:
measure: Difference in horizontal distance stratified by body mass index
timeFrame: 12 months
measure: Difference in horizontal distance stratified by presence of pre-eclampsia
timeFrame: 12 months
measure: Difference in horizontal distance stratified by presence of pregnancy induced hypertension
timeFrame: 12 months
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Guy's Hospital, Great Maze Pond
Study officials:
affiliation: Guys' & St Thomas' NHS Foundation Trust
name: Gill Arbane, BSc
role: STUDY_CHAIR
References:
Clinical trial NCT05856929: Sexual Dysfunction After Renal Transplantation
Official title: Sexual Function and Reproductive Function of Kidney Transplant Recipients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sexual Dysfunction
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2023-05-12
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who have undergone kidney transplantation for more than six months

Brief summary: A questionnaire will be send to kidney transplant recipients to investigate characteristics of them and their sexual function, all participants in the survey are anonymous and voluntary, then analyse these characteristics.


Eligibility criteria: Inclusion Criteria:

* patients who have undergone kidney transplantation for more than six months

Exclusion Criteria:

* having no sexual partner, being under 18 or over 70 years of age, exhibiting abnormal mental behavior, having poor understanding and communication ability, having low intelligence, or having a congenital sexual disorder

Primary outcomes:
measure: the number of participants is up to 500
timeFrame: 2024.06
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shaanxi
city: Xi'an
country: China
facility: Department of Urology
Study officials:
References:
Clinical trial NCT01622829: Activity on Prescription to Promote Physical Activity in Hospitalized Patients
Official title: Pilot Study on Physical Activity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Physical Activity
Lead sponsor: Heidelberg University
Sponsor class: OTHER
First posted: 2012-06-19
Enrollment: 120
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: This study tries to improve patient's activity by a "Prescription for Activity" led by physiotherapists in secondary health care setting.

Three groups are compared in regard to their increase of physical activity.


Eligibility criteria: Inclusion Criteria:

* aged 40-75 years
* self-dependent
* walk around at home alone
* German-speaking
* Ability to read and write
* Life expectancy \> 6 months
* Stable disease process expected for the next 6 months
* Time spend in hospital: \> 3 days, \< 4 weeks

Exclusion Criteria:

* Patients suffering from dementia
* Planned participation in rehabilitation
* severe functional limitations that precluded any increase in physical activity
* not living independently

Primary outcomes:
measure: Change from baseline in levels of physical activity at three months
timeFrame: Baseline, 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Departement of Sports Medicine, University of Heidelberg
Study officials:
References: